Ignite Creation Date:
2025-12-24 @ 7:32 PM
Ignite Modification Date:
2026-01-01 @ 11:08 PM
Study NCT ID:
NCT02448303
Status:
COMPLETED
Last Update Posted:
2019-09-12
First Post:
2015-05-14
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer
Sponsor:
Acerta Pharma BV
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-05
Start Date Type:
ACTUAL
Primary Completion Date:
2018-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-06
Completion Date Type:
ACTUAL
First Submit Date:
2015-05-14
First Submit QC Date:
None
Study First Post Date:
2015-05-19
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2019-07-19
Results First Submit QC Date:
None
Results First Post Date:
2019-09-12
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-08-22
Last Update Post Date:
2019-09-12
Last Update Post Date Type:
ACTUAL